4-AcO-MiPT

Discovery

4-HO-MiPT (miprocin), the active metabolite of 4-AcO-MiPT, was first synthesized by David Repke as part of a systematic investigation of psilocin analogs with varied N,N-dialkyl substituents.^[6] Alexander Shulgin evaluated 4-HO-MiPT in self-experiments by 1979, describing 12 mg as "richly insightful and highly erotic" and identifying it as the most interesting member of his oxygen-substituted MiPT series.^[2] The acetate ester prodrug was subsequently prepared alongside 4-AcO-DMT and 4-AcO-DET, with the acetyloxy group improving chemical stability over the oxidation-prone free phenol.^[3]

Research chemical emergence

4-AcO-MiPT appeared on online research chemical markets in the late 2000s, typically as the fumarate salt, marketed alongside other 4-substituted tryptamine prodrugs as a legal alternative to psilocybin mushrooms.^[3] No institutional research program or therapeutic development pathway has been identified for the compound. A 2023 patent covering crystalline forms of miprocin suggests emerging commercial interest in the pharmacological target, though no clinical program has been announced.^[7]

Pharmacological characterization

Formal pharmacological study proceeded slowly. Crystal structures of the active metabolite were reported in 2019 and 2020.^[8][9] The pivotal dataset appeared in 2023, when Kozell et al. published binding affinity and functional potency data for both 4-AcO-MiPT and 4-OH-MiPT at serotonin receptors.^[1] In the same year, Wallach et al. identified Gq-pathway signaling as the key predictor of psychedelic potential across the tryptamine class.^[4] Hill et al. (2025) reported behavioral effects in rodent models following DEA designation of 4-OH-MiPT as a tryptamine derivative of concern.^[10]

Structural class

4-AcO-MiPT belongs to the 4-substituted tryptamine family — indole alkaloid derivatives defined by oxygenated substitution at the 4-position of the indole ring. It is the acetate ester prodrug of 4-HO-MiPT, paralleling the relationship between psilocybin and psilocin. The defining structural feature is its asymmetric N-methyl-N-isopropyl substitution on the ethylamine side chain, placing it between the compact 4-AcO-DMT (N,N-dimethyl) and the bulkier 4-AcO-DiPT (N,N-diisopropyl) in structural space.^[11]

Molecular properties

The molecule comprises an indole bicyclic ring system with an acetyloxy group at C-4 and a 2-(N-methyl-N-isopropylamino)ethyl chain at C-3.^[12] The acetate ester at C-4 is the site of hydrolytic cleavage that converts the prodrug to its active 4-hydroxy metabolite in vivo. The asymmetric tertiary amine generates greater steric bulk than 4-AcO-DMT but less than 4-AcO-DiPT, influencing receptor binding geometry.

Stereochemistry

4-AcO-MiPT contains no chirality centers. The molecule is achiral — no enantiomers or diastereomers exist, and all preparations consist of a single molecular species.^[12]

Physical properties

No published data on melting point, solubility, or chemical stability of 4-AcO-MiPT exist in either free base or salt form. The compound has been commercially distributed as the fumarate salt.^[3]

Crystal structure data exist only for the active metabolite 4-HO-MiPT: Chadeayne et al. determined the fumarate monohydrate structure in 2019,^[8] followed by a bis(miprocinium) fumarate salt form in 2020.^[9] These apply to the metabolite reference standard, not 4-AcO-MiPT itself.

Mechanism of action

4-AcO-MiPT functions as a prodrug. The 4-acetoxy ester undergoes hydrolysis in vivo to yield 4-HO-MiPT (miprocin), the pharmacologically active form. This is supported by the approximately 7-fold difference in serotonin receptor binding between the parent ester and the free hydroxyl metabolite,^[1] and corroborated by animal studies showing 4-hydroxy tryptamines are consistently more potent than their 4-acetoxy counterparts.^[13]

The primary target is the serotonin 5-HT₂A receptor, where 4-OH-MiPT acts as a partial agonist through the Gq signaling pathway.^[1] Gq-pathway activation at 5-HT₂A — rather than beta-arrestin2 recruitment — predicts psychedelic potential across the tryptamine class.^[4]

Secondary targets include the 5-HT₂C receptor (near-full agonism) and 5-HT₁A (moderate agonism), both contributing to the broader experiential profile.^[1] Downstream effects are expected to include glutamate receptor modulation and neuroplasticity cascades, consistent with the serotonergic psychedelic class.^[14]

The active metabolite also shows moderate affinity at the SERT (SERT).^[1] At typical doses this is unlikely to drive the primary experience, but it becomes clinically relevant in combination with other serotonergic agents.

Pharmacokinetics

No human pharmacokinetic data exist specifically for 4-AcO-MiPT. All parameters below are inferred from structural analogs.

Metabolic studies of the related 4-AcO-DiPT in human liver cells identified ester hydrolysis as the primary pathway, followed by glucuronidation, sulfation, and minor oxidative metabolism.^[15] By analogy, 4-AcO-MiPT is expected to undergo the same ester cleavage to yield 4-OH-MiPT. This parallels the well-characterized conversion of psilocybin to psilocin.^[16]

Reference data from psilocin pharmacokinetics suggest oral bioavailability around 50%, peak plasma levels at 2–4 hours, and an half-life of 1.5–4 hours.^[16] These values provide an approximate frame, but the bulkier N-isopropyl group of 4-OH-MiPT may alter clearance rates.inferred

Where it acts

No direct neuroimaging data exist for 4-AcO-MiPT. By class inference from its 5-HT₂A partial agonist pharmacology, the active metabolite is expected to act on layer V cortical pyramidal neurons, disrupting default mode network integrity and reducing thalamocortical gating.^[14] The result is increased global connectivity and neural entropy — experienced as perceptual intensification, loosened associative thinking, and visual pattern generation.

The co-engagement of 5-HT₂A and 5-HT₁A receptors produces the balance characteristic of tryptamine psychedelics: perceptual amplification driven by 5-HT₂A alongside a contemplative, anxiolytic undercurrent from 5-HT₁A.^[14]

Why it matters

Serotonergic psychedelics activate neuroplasticity cascades downstream of 5-HT₂A — promoting structural changes in neurons that may underlie persisting psychological shifts after acute experiences.^[14] 4-AcO-MiPT's partial agonism falls within the range associated with psychoplastogenic potential, though this has not been directly tested. The REBUS framework (Relaxed Beliefs Under Psychedelics) offers context: partial 5-HT₂A agonism would be expected to moderately loosen the precision of prior beliefs, permitting new sensory and cognitive patterns without complete ego dissolution.

Toxicity

No lethal dose data exist for 4-AcO-MiPT in any species, and no therapeutic index can be calculated. No published case reports of adverse events, overdose, or death specifically attributable to this compound have been identified.safety citation needed A 2022 systematic review of novel psychoactive substance adverse events from 2017–2020 found no confirmed cases involving 4-AcO-MiPT or its metabolite.^[17]

Class-level data provide the only available context: tryptamine NPS intoxications can include rapid heart rate, elevated blood pressure, elevated body temperature, seizures, and serotonin syndrome — particularly when combined with serotonergic agents or MAOIs.^[18] Polydrug use complicates attribution of effects to individual compounds in emergency presentations.^[19]

Psychological Risks

No controlled data on psychological risks exist. By class inference from serotonergic psychedelics:

• Acute psychological distress: anxiety, panic, paranoia, and dysphoric crisis can occur at any dose but are more likely above 20 mg, in unsupported settings, or in predisposed individuals
• Psychosis precipitation: Serotonergic psychedelics can trigger psychotic episodes in individuals with personal or family history of psychotic spectrum disorderssafety citation needed
• HPPD: Hallucinogen persisting perception disorder is reported across the psychedelic class; no specific reports are linked to 4-AcO-MiPTsafety citation needed
• Thought loops: Reported among cognitive effects, contributing to acute distress at higher doses

The compound's partial agonism at 5-HT₂A suggests an intrinsic ceiling on effect intensity relative to full agonists, but this does not eliminate psychological risk.inferred

Tolerance & Dependence

Rapid tolerance develops via 5-HT₂A downregulation following agonist exposure.^[4] Community consensus places tolerance onset at near-immediate, with full reset within approximately 7 days.inferred Cross-tolerance with other serotonergic psychedelics — including LSD, psilocybin, and DMT — is expected via the shared mechanism.^[4]

4-AcO-MiPT is not considered habit-forming. No evidence of physical dependence, withdrawal, or escalating use patterns has been documented. Substituted tryptamines show stimulus generalization with other psychedelics in animal models, but this reflects shared receptor pharmacology rather than compulsive self-administration.^[13]

Drug Interactions

Tramadol: Dangerous combination. Tramadol inhibits serotonin reuptake while acting as an opioid agonist.^[20] Combined with 5-HT₂A agonism, this creates clinically significant serotonin syndrome risk.^[5] Tramadol-induced serotonin syndrome is documented in published case series.^[21]

MAOIs: Dangerous combination. MAO-A inhibitors block serotonin degradation; combined with a 5-HT₂A agonist, severe potentiation of both psychedelic effects and serotonin toxicity is expected.^[18]safety citation needed

SSRIs/SNRIs: Chronic SSRI use attenuates psychedelic effects via 5-HT₂A downregulation. Acutely, the combination increases serotonin syndrome risk.^[5]

Contraindications

No published contraindication data specific to 4-AcO-MiPT exist. The following are inferred from pharmacological class:

• Psychotic disorders and schizophrenia spectrum (personal or family history): Absolute contraindicationsafety citation needed
• Concurrent MAOI use: Absolute contraindication — severe serotonin syndrome risk^[18]
• Concurrent tramadol use: Absolute contraindication — serotonin syndrome risk^[5]
• Bipolar disorder: Relative contraindication — may trigger manic episodessafety citation needed
• Heart conditions: Relative contraindication — sympathomimetic effects expectedsafety citation needed
• Pregnancy and breastfeeding: Standard precautionary contraindication — no reproductive data existsafety citation needed

All contraindications are class-level inference. No substance-specific studies have been conducted.

4-AcO-MiPT occupies an ambiguous legal position in most jurisdictions. As an unscheduled tryptamine in several major markets — including the United States and Canada — it has circulated as a research chemical, though structural analog act provisions may apply where the compound is sold for human consumption. A growing number of European jurisdictions have explicitly controlled it through blanket tryptamine scheduling or novel psychoactive substance legislation.^[22][3]

All legal status data is sourced from community databases and should be independently verified. Scheduling status can change without notice; readers should consult current legislation in their jurisdiction.